PIPELINE
Advancing novel compounds across a range of indications

South Rampart’s proprietary compounds have the potential to provide relief for patients with many types of pain including chronic, acute post-operative and emergency room, and neuropathic pain.

To explore the full range of possibilities offered by our promising novel molecules, South Rampart Pharma is working with top medicinal chemists to develop oral and intravenous formulations optimized for specific clinical indications. Preclinical and IND-enabling studies indicate that SRP compounds have broad potential applicability within a wide range of different pain applications.

Innovation Pipeline

BROAD THERAPEUTIC POTENTIAL, ADDRESSING MULTIPLE PAIN MECHANISMS & FEVER

South Rampart Pharma’s lead clinical entity, SRP-001 is currently undergoing Phase 1 trials evaluating the safety, tolerability, and pharmacokinetics of single and multiple ascending oral doses of the study drug. Results are expected in Q2 2023.

Check back here for more updates on the clinical status of SRP compounds or visit our clinical trials portal for details about participating in one of our clinical trials.